


LARGE SCALE EXPRESSION ANALYSIS

Evolution and Revolution



Current Topics in Genome Analysis 2014

Paul Meltzer

*No Relevant Financial Relationships with
Commercial Interests*



**WHOLE GENOME APPROACHES TO
BIOLOGICAL QUESTIONS**

**GENE EXPRESSION
GENE VARIATION
GENE FUNCTION**

**TRANSCRIPTOMICS IS IMPORTANT TO
ALL OF THESE**

SOME IMPORTANT ISSUES TO CONSIDER

- **LARGE DYNAMIC RANGE**
- **LARGE NUMBER OF GENES**
- **SAMPLE NUMBER USUALLY MUCH SMALLER THAN GENE NUMBER**
 - **NOT ALL TRANSCRIPTS ARE KNOWN**
- **ALL TECHNOLOGIES ARE IMPERFECT WITH VARIOUS LIMITATIONS AND IMPERFECTIONS**
- **ANALYTICAL TOOL DEVELOPMENT LAGS BEHIND DATA GENERATION TECH DEVELOPMENT**



MICROARRAY TERMINOLOGY

- **Feature--an array element**
- **Probe--a feature corresponding to a defined sequence**
- **Target--a pool of nucleic acids of unknown sequence**

POSSIBLE ARRAY FEATURES



- **Synthetic Oligonucleotides**
- **PCR products from**
Cloned DNAs
Genomic DNA
- **Cloned DNA**


OLIGONUCLEOTIDE ARRAY DESIGN

- **Extremely flexible**
 - 3' bias
 - full length
 - exon specific
 - candidate transcripts
 - miRNAs
- **Very high density possible**
- **Requires sequence data**

Microarray Manufacture

- **Printing**
- **Synthesis *in situ***
 - light directed
 - mechanically directed





RANDOMLY POSITIONED HIGH DENSITY
ARRAYS OF ADDRESSABLE OLIGONUCLEOTIDES
COUPLED TO BEADS

Labelled
cRNA

Address Probe

29b 50b

The image shows a microarray bead array on the left and a schematic diagram on the right. The schematic shows a grey bead with a red 'Address' region (29b) and a green 'Probe' region (50b). A blue 'Labelled cRNA' molecule is hybridized to the probe region, with orange circles representing fluorescent labels.

MICROARRAY READOUT

- Determine quantity of target bound to each probe in a complex hybridization
- Must have high sensitivity, low background
- High spatial resolution essential
- Dual channel capability useful
- Fluorescent tags meet these demands

Laboratory Essentials

- Arrays
- Hybridization and Wash Equipment
- Scanner
- Software for processing array image
- Software for data analysis and display
- Bioinformatics collaborator

Accessing Expression Data

- Individual Lab and Journal Sites; public databases

The screenshot shows the GEO Overview page. The 'General overview' section lists three main goals: 1. Provide a robust, versatile database for high-throughput functional genomic data. 2. Offer simple submission procedures and formats. 3. Provide user-friendly mechanisms for querying, reviewing, and downloading data. The 'Data organization' section includes a diagram illustrating the relationship between Platform, Samples, Series, DataSet, and Profile records.

Currently contains
expression data on
1,131,582 samples.

<http://www.ncbi.nlm.nih.gov/geo/>

Accessing Expression Data

The screenshot shows the ArrayExpress website interface. At the top, the address bar displays <http://www.ebi.ac.uk/arrayexpress/>. The EMBL-EBI logo is prominent, with the text "European Bioinformatics Institute" below it. A navigation menu includes "EBI Home", "About EBI", "Research", "Services", "Toolbox", "Databases", "Downloads", and "Submissions". The "Databases" menu is expanded to show "ARRAYEXPRESS DATABASE".

The main content area is titled "ArrayExpress at the EBI". It describes ArrayExpress as a public repository for microarray data, aimed at storing well-annotated data in accordance with MIQE recommendations. A "Current Content Overview" table provides the following statistics:

Category	Count	Action
Experiments	66	View
Arrays	89	View
Protocols	459	View
Hybridizations	142	

Below the overview, there is an "Announcement" section stating: "There will now no longer be any (planned) downtime on the 1st November, and it should be business as usual. The next most likely time for a scheduled EBI-wide power down will be the 7th February 2014." A contact email arrayexpress@ebi.ac.uk is provided for comments or issues.

On the right side, a "Latest News" section highlights a "New MIAMEexpress Release 1.5" (08/10/2013) and a "Mapping the MAGE-OM to data within the Stanford Microarray Database" (2006/02/03).

<http://www.ebi.ac.uk/microarray-as/ae/>



Publishing Expression Data

- MIAME standard

Minimum Information about a Microarray Experiment

- Format required by many journals
- Essential for database submissions

<http://www.mged.org/Workgroups/MIAME/miame.html>



Output of Microarray Analysis:

**expression ratio
(2 color hybridization)**

or

**relative expression level
(1 color hybridization)**

**Both types of data can be analyzed with
essentially the same tools.**

APPLICATIONS OF EXPRESSION ARRAYS

- **Expression profiling of tissue specimens**

Power arises from increasing sample number

- **Direct comparisons (Induction, Knockdown etc.)**

Biological system critical

A RECURRING PROBLEM

Disease Genes

Transcription factors

Hormones/growth factors

Drugs

Toxins

Infectious agents

Physical agents

siRNA's



?????

Downstream Genes

•Direct targets

•Indirect targets

EXPRESSION DATA ANALYSIS

•Large amount of data

Examples: 200 samples x 25000 probes= 5,000,000 data points

•Requires analysis and visualization tools

Overview of microarray bioinformatics:
Simon R, Curr Opin Biotechnol. 2008 Feb;19(1):26-9.

EXPRESSION DATA ANALYSIS

- Check quality of individual experiments

- Preprocessing

- Normalization

- Remove genes which are not accurately measured

- Remove genes which are similarly expressed in all samples

- Unsupervised Analysis

- Supervised Analysis

Unsupervised Analysis

How do genes and samples cluster into groups?

Powerful method of data display.



Does not prove the validity of groups.



- Clustered Samples Are Biologically Similar



- Clusters of Co-expressed genes


- May be functionally related


- May be enriched for pathways











Supervised Analysis


What genes distinguish samples in selected groups from each other?


- Choice of groups can be based on any known property of the samples.
- Many possible underlying methods: t-test or F-statistic frequently used.
- Output includes ranked gene list.
- Leads to the development of classifiers which can be applied to unknown samples.
- Must address the problem of false discovery due to multiple comparisons and discrepancy between sample/gene numbers.

SUPERVISED METHODS GENERATE RANKED GENE LISTS

TOP DISCRIMINATORS FOR GIST

<u>Rank</u>	<u>Weight</u>	<u>Gene Description</u>
1	7.55575	<u>v-kit sarcoma oncogene</u>
2	6.48306	G coupled receptor 20
3	4.60057	G coupled receptor 20
4	4.51681	annexin A3
5	3.33057	KIAA0353 protein
6	3.31734	phosphofructokinase
7	2.95095	DKFZP434N161 n
8	2.83435	protein kinase C, theta
9	2.79721	butyrylcholinesterase
10	2.72752	annexin A3





**SIGNAL STRENGTH VARIES IN
TISSUE PROFILING EXPERIMENTS**

**THE MOST INTERESTING QUESTIONS
TEND TO BE ASSOCIATED WITH
WEAKER SIGNAL.**

A CONTINUUM OF POSSIBLE OUTCOMES FROM MICROARRAY RESEARCH

- SOME FEATURES WILL SEPARATE SAMPLES EASILY INTO CLASSES, AND MIGHT BE REDUCED TO SINGLE GENE TESTS, IMPLEMENTED IN A CONVENTIONAL FASHION.
- OTHERS WILL BE MORE DIFFICULT, AND REQUIRE MULTIPLE GENE MEASUREMENTS.
- MANY CLINICALLY RELEVANT FEATURES APPEAR TO FALL WITHIN THIS DIFFICULT GROUP.

A CONTINUUM OF POSSIBLE OUTCOMES FROM MICROARRAY RESEARCH

- SOME GENES WILL SHOW DIFFERENCES BETWEEN GROUPS OF SAMPLES BY CHANCE ALONE.
- THERE MAY BE NO ONE GENE WHICH SEPARATES GROUPS RELIABLY.
- FIND THE MOST INFORMATIVE GENES AND USE THEM IN COMBINATION .

RISK OF OVERFITTING IN CLINICAL STUDIES WITH SMALL SAMPLE SETS

NEED INDEPENDENT VALIDATION SETS.

J Natl Cancer Inst. 2007 Jan 17;99(2):147-57.

Critical review of published microarray studies for cancer outcome and guidelines on statistical analysis and reporting. Dupuy A, Simon RM.

BACKGROUND: Both the validity and the reproducibility of microarray-based clinical research have been challenged. There is a need for critical review of the statistical analysis and reporting in published microarray studies that focus on cancer-related clinical outcomes. **METHODS:** Studies published through 2004 in which microarray-based gene expression profiles were analyzed for their relation to a clinical cancer outcome were identified through a Medline search followed by hand screening of abstracts and full text articles. Studies that were eligible for our analysis addressed one or more outcomes that were either an event occurring during follow-up, such as death or relapse, or a therapeutic response. We recorded descriptive characteristics for all the selected studies. A critical review of outcome-related statistical analyses was undertaken for the articles published in 2004. **RESULTS:** Ninety studies were identified, and their descriptive characteristics are presented. Sixty-eight (76%) were published in journals of impact factor greater than 6. A detailed account of the 42 studies (47%) published in 2004 is reported. **Twenty-one (50%) of them contained at least one of the following three basic flaws:** 1) in outcome-related gene finding, an unstated, unclear, or inadequate control for multiple testing; 2) in class discovery, a spurious claim of correlation between clusters and clinical outcome, made after clustering samples using a selection of outcome-related differentially expressed genes; or 3) in supervised prediction, a biased estimation of the prediction accuracy through an incorrect cross-validation procedure. **CONCLUSIONS:** The most common and serious mistakes and misunderstandings recorded in published studies are described and illustrated. Based on this analysis, a proposal of guidelines for statistical analysis and reporting for clinical microarray studies, presented as a checklist of "Do's and Don'ts," is provided.

MICROARRAY STUDIES GENERATE ORGANIZED LIST OF GENES

- Often cryptic and hard to interpret.
- Hypothesis generating, but this is often rather subjective.
- Seldom provide strong evidence for a specific mechanism.
- Expression data is intrinsically limited.

GETTING BEYOND GENE LISTS

- Optimal use of gene annotations.
 - Gene Ontology
(<http://david.abcc.ncifcrf.gov/>)
- Optimizing use of public data.
 - GEO, ARRAY EXPRESS, ACADEMIC DATA
 - GENE SIGNATURE BASED METHODS (Gene Set Enrichment Analysis).

GSEA
Gene Set Enrichment Analysis

GSEA Home Downloads Molecular Signatures Database Documentation Contact

MSigDB
Molecular Signatures Database

Molecular Signatures Database v3.0

Overview

The Molecular Signatures Database (MSigDB) is a collection of annotated gene sets for use with GSEA software. From this web site, you can

- Search for gene sets by keyword.
- Browse gene sets by name or collection.
- Examine a gene set and its annotations. See, for example, the *ANGIOGENESIS* gene set page.
- Download gene sets.
- Investigate gene sets:
 - Compute overlaps between your gene set and gene sets in MSigDB.
 - Categorize members of a gene set by gene families.
 - View the expression profile of a gene set in any of the three provided public expression compendia.

Registration

Please register to download the GSEA software and view the MSigDB gene sets. After registering, you can log in at any time using your email address. Registration is free. Its only purpose is to help us track usage for reports to our funding agencies.

Current Version

MSigDB database v3.0 updated Sep 9, 2010. Release notes.
 GSEA/MSigDB web site v3.82 released Oct 7, 2011

Contributors

The MSigDB is maintained by the GSEA team with the support of our MSigDB Scientific Advisory Board. We also welcome and appreciate contributions to this shared resource and encourage users to submit their gene sets to genesets@broadinstitute.org. Our thanks to our many contributors.

Funded by: National Cancer Institute, National Institutes of Health, National Institute of General Medical Sciences.

Collections

The MSigDB gene sets are divided into five major collections:


- C1 positional gene sets** for each human chromosome and each cytogenetic band.
- C2 curated gene sets** from online pathway databases, publications in PubMed, and knowledge of domain experts.
- C3 motif gene sets** based on conserved cis-regulatory motifs from a comparative analysis of the human, mouse, rat and dog genomes.
- C4 computational gene sets** defined by expression neighborhoods centered on 380 cancer-associated genes.
- C5 GO gene sets** consist of genes annotated by the same GO terms.

Citing the MSigDB

To cite your use of the Molecular Signatures Database (MSigDB), please reference Subramanian, Tamayo, et al. (2005, PNAS 102, 15545-15550) and also the source for the gene set as listed on the gene set page.

Contact Us

If you have comments or questions, please contact us: gsea@broadinstitute.org.





WHAT TO LOOK FOR IN CLINICAL CORRELATIVE STUDIES USING MICROARRAYS

- WELL DEFINED QUESTION AND PATIENT SAMPLE.
- HIGH QUALITY ARRAY MEASUREMENTS (HARD TO ASSESS WITHOUT REFERENCE TO PRIMARY DATA---SHOULD BE MADE PUBLIC).
- APPROPRIATE AND RIGOROUS STATISTICAL ANALYSIS OF ARRAY DATA.
- FORMAL CLASSIFIER THAT CAN BE APPLIED TO NEW SAMPLES.
- VALIDATION SAMPLE SET.

WHAT TO LOOK FOR IN CLINICAL
CORRELATIVE STUDIES
USING MICROARRAYS

- **GOAL SHOULD BE TO SEEK AND VALIDATE CLINICALLY RELEVANT SIGNATURES WITHIN DEFINED PATIENT GROUPS FOR WHICH NO CURRENT FEATURES ADEQUATELY ANSWER THE CLINICAL QUESTION POSED.**

EXPRESSION PROFILING IN THE CLINIC?

PROBLEMS:

- **SPECIALIZED TECHNOLOGY**
- **RNA IS UNSTABLE**
- **FROZEN TISSUE NOT PART OF USUAL OR SAMPLE FLOW**

EXPRESSION PROFILING IN THE CLINIC?


OPTIONS:

- REFERENCE LABORATORIES
 - RNA PRESERVATIVES
 - USE OF PARAFFIN EMBEDDED MATERIALS.
- USE ARRAYS FOR DISCOVERY TO EXTRACT SIGNATURES WHICH CAN BE ASSAYED WITH ALTERNATIVE TECHNOLOGIES.

FDA APPROVED TESTS FOR BREAST CANCER BASED ON EXPRESSION STUDIES


70 GENE MICROARRAY SIGNATURE



Van de Vijver et al
NEJM 347:1999 .




Multigene RT-PCR Signature

Paik et al NEJM 351:2817





PubMed Citations for RNA-Seq



[The transcriptional landscape of the yeast genome defined by RNA sequencing.](#)
Nagalakshmi U, Wang Z, Waern K, Shou C, Raha D, Gerstein M, Snyder M.
Science. 2008 Jun 6;320(5881):1344-9

-

[Dynamic repertoire of a eukaryotic transcriptome surveyed at single-nucleotide resolution.](#)
Wilhelm BT, Marguerat S, Watt S, Schubert F, Wood V, Goodhead I, Penkett CJ, Rogers J, Bähler J.
Nature. 2008 Jun 26;453(7199):1239-43. Epub 2008 May 18.

-


[Mapping and quantifying mammalian transcriptomes by RNA-Seq.](#)
Mortazavi A, Williams BA, McCue K, Schaeffer L, Wold B.
Nat Methods. 2008 Jul;5(7):621-8. Epub 2008 May 30.




ARRAYS VS. NEXT GENERATION SEQUENCING

- ARRAY TECHNOLOGIES MEASURE THE RELATIVE ABUNDANCE OF NUCLEIC ACIDS OF DEFINED SEQUENCE IN A COMPLEX MIXTURE.
- SEQUENCING CAN ACCOMPLISH THE SAME THING.


When Worlds Collide




Microarray Expression Profiling



Genome Sequencing





- MANY NEW OPPORTUNITIES
- MANY NEW CHALLENGES

ARRAYS VS. NEXT GENERATION SEQUENCING

MICROARRAYS	SEQUENCING
<ul style="list-style-type: none"> • READILY AVAILABLE MATURE TECHNOLOGY • RELATIVELY INEXPENSIVE • EFFECTIVE WITH VERY COMPLEX SAMPLES • HUNDREDS OF SAMPLES PRACTICAL • CAN TARGET SUBSET OF GENOME 	<ul style="list-style-type: none"> • WHOLE GENOME DATA • RELATIVELY UNIFORM ANALYTICAL PIPELINE • FREE OF HYBRIDIZATION ARTIFACTS • LARGE DYNAMIC RANGE • POSSIBILITY OF ONE PLATFORM FOR ALL APPLICATIONS
PROS	
MICROARRAYS	SEQUENCING
<ul style="list-style-type: none"> • REQUIRE PLATFORM AND APPLICATION SPECIFIC DATA PROCESSING • PRONE TO PLATFORM SPECIFIC ARTIFACTS • LIMITED DYNAMIC RANGE • SOME PROBES PERFORM POORLY • MANY SOURCES OF NOISE • WHOLE GENOME STUDIES MAY REQUIRE MANY ARRAYS, INCREASING SAMPLE REQUIREMENTS AND COMPLICATING ANALYSIS 	<ul style="list-style-type: none"> • EVOLVING TECHNOLOGY • TECHNOLOGY SPECIFIC ARTIFACTS • RESOURCE INTENSIVE • COMPUTATIONALLY INTENSIVE • NO STANDARD ANALYSIS YET • LOWER SAMPLE THROUGHPUT
CONS	

MEASURING GENE EXPRESSION BY RNA SEQUENCING

ADVANTAGES

- RNA SEQUENCE VARIATIONS DETECTED AT SINGLE NUCLEOTIDE RESOLUTION
 - ALLELE SPECIFIC EXPRESSION
 - MUTATIONS
 - RNA EDITING
- RNA STRUCTURE: SPLICING, START SITES, TERMINATION SITES; REARRANGEMENTS
- DETECTED SIGNALS ARE RELATIVELY UNAMBIGUOUS; POTENTIAL TO OUTPERFORM MICROARRAY
- TRANSCRIPT DISCOVERY

MEASURING GENE EXPRESSION BY RNA SEQUENCING


- FULL LENGTH mRNA----RNA-Seq
- TAG SEQUENCING (SAGE-LIKE)
- PolyA vs. Total (ribosomal depleted)
- Strand specific vs. non-strand specific
- miRNA
- lincRNA


MEASURING GENE EXPRESSION BY RNA SEQUENCING: PROS AND CONS

LIMITATIONS

- LOWER LIMIT OF DETECTION IS CONSTRAINED BY THE mRNA ABUNDANCE DISTRIBUTION AND THE NUMBER OF ALIGNED READS PER SAMPLE.
- LARGE SAMPLE NUMBERS DIFFICULT TO PROCESS WITHOUT AUTOMATION.
- SOFTWARE IS STILL EVOLVING: REQUIRES SOPHISTICATED BIOINFORMATICS COLLABORATION.
- COMPUTATIONAL HARDWARE REQUIREMENTS ARE SUBSTANTIAL
- LIBRARY PREP METHODS EVOLVING.
- DATA COMPARISON PROBLEMATIC IF METHODS DIFFER.

MEASURING GENE EXPRESSION BY RNA SEQUENCING





3' TAG SEQUENCING

- SEQUENCES ALIGNED AND COUNTED
- LIBRARIES OF TAGS FROM MANY SAMPLES CAN BE IDENTIFIED BY ADDING A “BARCODE” AND POOLED BEFORE SEQUENCING
- POTENTIAL TO ANALYZE LARGE NUMBERS OF SAMPLES IN PARALLEL

RNASeq COMPUTATIONAL WORKFLOW

RAW READS
↓
ALIGN

RNASeq COMPUTATIONAL WORKFLOW

RAW READS




ALIGN



TO WHAT???

- GENOME?
- TRANSCRIPTOME?
- WHICH TRANSCRIPTOME? REFSEQ? EMBL? CUSTOM?

WHAT ALIGNER????

RNA-seq Alignment






Models for RNA-seq

- Count-based models
- Multi-reads (isoform resolution)
- Paired-end reads (include length resolution step)
- Positional bias along transcript length
- Sequence bias

Read Counting

	union	intersection_strict	intersection_nonempty
	gene_A	gene_A	gene_A
	gene_A	no_feature	gene_A
	gene_A	no_feature	gene_A
	gene_A	gene_A	gene_A
	gene_A	gene_A	gene_A
	ambiguous	gene_A	gene_A
	ambiguous	ambiguous	ambiguous

Sequence Bias in RNA-Seq



Hansen et al. Biostatistics 13:204-216 (2012)

Result of Quantification

	A	B	C	D	E	F	G
	Ensembl.Gene	HGNC.symbol	length	adipose	adrenal	brain	breast
1	ENSG000000000	TSPAN6	5150	6.5102076	4.4399499	4.47541785	6.19290729
2	ENSG000000000	TNMD	1881	4.77434788	3.03741631	-2.30427166	6.20206438
3	ENSG000000000	DPM1	7899	4.67436267	5.14359648	5.0350925	5.03635496
4	ENSG000000000	SCYL3	12929	2.61653185	3.44062654	3.04429556	3.19008304
5	ENSG000000000	C1orf112	21973	2.23079247	2.2412008	1.59208827	2.33934858
6	ENSG000000000	FGR	15989	5.13218607	4.64955569	1.82875376	3.22232919
7	ENSG000000000	CFH	17278	7.31413745	7.75995914	5.29604675	7.69713191
8	ENSG000000000	FUCA2	4576	5.99712898	5.74841489	5.01716452	6.08121442
9	ENSG000000000	GCLC	17290	5.41823808	5.95937652	6.49950722	6.56422871
10	ENSG000000000	NFYA	5471	4.59377563	4.23783092	4.78376968	4.50642521
11	ENSG000000000	C1orf201	25360	2.59820197	2.71831835	4.21443513	3.15709964
12	ENSG000000000	NIPAL3	15545	4.40544708	4.85233419	7.83920432	5.08638068
13	ENSG000000000	LAS1L	15066	5.11482973	5.55638125	5.0521603	4.73990806
14	ENSG000000000	ENPP4	9173	5.97080384	5.20063279	7.33245181	6.00612757
15	ENSG000000000	SEMA3F	15469	6.47286323	4.83802467	2.34795406	3.82755053
16	ENSG000000000	CFTR	18020	-1.01862313	-8.20277874	0.06918673	-4.77202424
17	ENSG000000000	ANKIB1	11241	5.44434018	5.60447554	6.78072994	6.04619478
18	ENSG000000000	CYP51A1	9653	1.01631067	-0.13131638	1.28723368	0.27236988
19	ENSG000000000	KRIT1	39656	4.59068842	5.25652479	5.09598679	4.93862567
20	ENSG000000000	RAD52	28855	2.36874662	3.83785346	2.80235076	3.13103594
21	ENSG000000000	MYH16	11845	-6.69104847	-3.34479775	-3.44177519	-3.98352835
22	ENSG000000000	BAD	5112	2.99253103	3.126457	2.6329015	3.44052741
23	ENSG000000000	LAP3	8517	6.71111978	7.70371262	6.75735727	6.77254509
24	ENSG000000000	CD90	6647	8.20711588	8.63102385	5.06827032	8.5406861

Differential Gene Expression

- A LARGE NUMBER OF VARIABLES INTRINSIC TO RNA-Seq ACCOMPANY THE DATA.
- THESE POSE A NEW SET OF COMPUTATIONAL PROBLEMS WHICH DIFFER SUBSTANTIALLY FROM THOSE ENCOUNTERED IN THE ANALYSIS OF MICROARRAY DATA.

Sonesson and Delorenzi *BMC Bioinformatics* 2013, **14**:91
<http://www.biomedcentral.com/1471-2105/14/91>



RESEARCH ARTICLE

Open Access

A comparison of methods for differential expression analysis of RNA-seq data

Charlotte Sonesson^{1*} and Mauro Delorenzi^{1,2}

Rapaport et al. *Genome Biology* 2013, **14**:R95
<http://genomebiology.com/2013/14/9/R95>



Abstract

Background: Finding genes that are differentially expressed understanding the molecular basis of phenotypic variation used extensively to quantify the abundance of mRNA. High-throughput sequencing of cDNA (RNA-seq) has emerged rapidly. To exploit the possibilities and address the challenges software packages have been developed especially for differential expression analysis of RNA-seq data.

Results: We conducted an extensive comparison of eleven methods and any results obtained under such conditions. All methods are freely available within the R framework. For reads mapping to each genomic feature of interest in each of on both simulated data and real RNA-seq data.

Conclusions: Very small sample sizes, which are still common evaluated methods and any results obtained under such conditions. All methods are freely available within the R framework. For reads mapping to each genomic feature of interest in each of on both simulated data and real RNA-seq data.

Keywords: Differential expression, Gene expression, RNA-seq

METHOD

Open Access

Comprehensive evaluation of differential gene expression analysis methods for RNA-seq data

Franck Rapaport¹, Raya Khanin¹, Yupu Liang¹, Mono Pirun¹, Azra Kjek'1, Paul Zumbo^{2,3}, Christopher E Mason^{2,3}, Nicholas D Socci¹ and Doron Betel^{1,4*}

Abstract

A large number of computational methods have been developed for analyzing differential gene expression in RNA-seq data. We evaluated common methods using the SEQC benchmark dataset by features, including normalization, accuracy of differential expression analysis when one condition has no detectable expression. We note that array-based methods adapted to RNA-seq data RNA-seq. Our results demonstrate that increasing the number of reads on power over increased sequencing depth.

Briefings in Bioinformatics Advance Access published December 2, 2013
BRIEFINGS IN BIOINFORMATICS, page 1 of 12

Comparison of software packages for detecting differential expression in RNA-seq studies

Fatemeh Seyednasrollah, Asta Laiho and Laura L. Elo
Submitted: 20th August 2013; Received (in revised form): 9th October 2013

PROTOCOL


Count-based differential expression analysis of RNA sequencing data using R and Bioconductor


Simon Anders¹, Davis J McCarthy^{2,3}, Yunshun Chen^{4,5}, Michal Okoniewski⁶, Gordon K Smyth^{4,7}, Wolfgang Huber¹ & Mark D Robinson^{8,9}

¹Genome Biology Unit, European Molecular Biology Laboratory, Heidelberg, Germany. ²Department of Statistics, University of Oxford, Oxford, UK. ³Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK. ⁴Bioinformatics Division, Walter and Eliza Hall Institute, Parkville, Victoria, Australia. ⁵Department of Medical Biology, University of Melbourne, Melbourne, Victoria, Australia. ⁶Functional Genomics Center UNI ETH Zurich, Switzerland. ⁷Department of Mathematics and Statistics, University of Melbourne, Melbourne, Victoria, Australia. ⁸Institute of Molecular Life Sciences, University of Zurich, Zurich, Switzerland. ⁹SIB Swiss Institute of Bioinformatics, University of Zurich, Zurich, Switzerland. Correspondence should be addressed to M.D.R. (mark.robinson@imls.uzh.ch) or W.H. (w.huber@embl.de).

Published online 22 August 2013; doi:10.1038/nprot.2013.099


RNA sequencing (RNA-seq) has been rapidly adopted for the profiling of transcriptomes in many areas of biology, including studies into gene regulation, development and disease. Of particular interest is the discovery of differentially expressed genes across different conditions (e.g., tissues, perturbations) while optionally adjusting for other systematic factors that affect the data-collection process. There are a number of subtle yet crucial aspects of these analyses, such as read counting, appropriate treatment of biological variability, quality control checks and appropriate setup of statistical modeling. Several variations have been presented in the literature, and there is a need for guidance on current best practices. This protocol presents a state-of-the-art computational and statistical RNA-seq differential expression analysis workflow largely based on the free open-source R language and Bioconductor software and, in particular, on two widely used tools, DESeq and edgeR. Hands-on time for typical small experiments (e.g., 4–10 samples) can be <1 h, with computation time <1 d using a standard desktop PC.





Fusion Gene Detection

Fusion gene schematic



Hindawi Publishing Corporation
BioMed Research International
Volume 2013, Article ID 340620, 6 pages
<http://dx.doi.org/10.1155/2013/340620>



Research Article

State-of-the-Art Fusion-Finder Algorithms Sensitivity and Specificity

**Matteo Carrara,¹ Marco Beccuti,² Fulvio Lazzarato,³ Federica Cavallo,¹ Francesca Cordero,²
Susanna Donatelli,² and Raffaele A. Calogero¹**

¹ Department of Molecular Biotechnology and Health Sciences, University of Torino, Via Nizza 52, 10126 Torino, Italy

² Department of Computer Science, University of Torino, C.So Svizzera 185, 10149 Torino, Italy

³ Unit of Cancer Epidemiology, Department of Biomedical Sciences and Human Oncology, University of Torino, 10126 Torino, Italy

Correspondence should be addressed to Raffaele A. Calogero; raffaele.calogero@unito.it

Received 4 October 2012; Revised 11 January 2013; Accepted 15 January 2013

Fusion Detection

TABLE 1: Filtering steps embedded in the algorithms.

Filters	Fusion finders							
	FF	THF	MS	FM	FH	DF	BF	CS
Pair distance	X					X	X	X
Anchor length		X			X			X
Read-through	X	X		X	X		X	
Junction-spanning				X	X		X	
PCR artifact				X	X		X	
Homology	X	X					X	
Quality			X	X				

FF: FusionFinder; THF: TopHat-fusion; MS: MapSplice; FM: FusionMap;
 FH: FusionHunter; DF: deFuse; BF: Bellerophon; CS: ChimeraScan.

False Positive Fusion Detection




FIGURE 4: False positive fusion detected using a synthetic dataset without chimeras. FF: FusionFinder; THF: TopHat-fusion; MS: MapSplice; FM: FusionMap; FH: FusionHunter; DF: defuse; BF: Bellerophon; CS: ChimeraScan.

WHEN IS RNA-Seq PREFERRED?

IT DEPENDS ON THE EXPERIMENTAL GOALS.

CURRENTLY

- RNA-Seq IS THE PREFERRED METHOD FOR ASSESSING TRANSCRIPT STRUCTURE AND SEQUENCE VARIATION AT GENOME SCALE.
- ROLE OF RNA-Seq FOR ROUTINE COUNT BASED EXPRESSION ANALYSIS IS LESS CLEAR AT THIS TIME.
- AS SEQUENCE THROUGHPUT INCREASES, COSTS DECLINE, AND AS STANDARDIZED ANALYTICAL PIPELINES FOR SPECIFIC EXPERIMENTAL GOALS ARE DEVELOPED, RNA-Seq WILL BECOME INCREASINGLY ATTRACTIVE FOR GENERAL USE.

USEFUL WEB SITES

MGED The Microarray Gene Expression Data Society:

<http://www.mged.org/>

NCBI Gene Expression Omnibus:

<http://ncbi.nlm.nih.gov/geo/>

NCBI Sequence Read Archive (SRA):

<http://www.ncbi.nlm.nih.gov/sra>

EBI Microarray informatics:

<http://www.ebi.ac.uk/microarray/index.html>

Stanford Microarray Database:

<http://smd.stanford.edu/>

UCSF DeRisi lab:

<http://derisilab.ucsf.edu/data/microarray/index.html>

Broad Institute:

Gene Set Enrichment Analysis (GSEA)

<http://www.broadinstitute.org/gsea/>

Connectivity Map:

<http://www.broadinstitute.org/cmap/>

Bioconductor

<http://bioconductor.org>

Biostars

<http://biostars.org>

RNA-seq blog

<http://www.rna-seqblog.com/>